Explore our strategy and projects
to learn about the future of our company
Results FY 2025 (€/MLN)
1,195
Revenues
394
Adjusted EBITDA
223
Adjusted net profit
209
Free cash flow
Stock price
Discover morePress releases
08/05/26 - 17:54
Price sensitiveRevenues and EBITDA in line with the expected quarterly revenue trend and impacted by a weak flu season. 2026 Guidance confirmed
04/05/26 - 17:45
Diasorin Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President
LIAISON PLEX® System: the new multiplexing platform of the Group
Diasorin's LIAISON PLEX® System and Respiratory Flex Assay Revolutionize Diagnostics with Flexibility and have Earned FDA Clearance.
Keep
in touch
Sign up for our investor alerts
and stay informed
on the latest developments